Summary LexaGene has just started sales of a revolutionary automated PCR machine that can test for 27 pathogens at once in about one hour.
It parallels Electrovaya, which have a recent 15 bagger on, a value nanocap stock in a highly favored sector that is likely to go profitable and have extreme growth.
I can find nothing wrong with the company as the management, market, technology and execution are all excellent.
Timing is perfect, they have just started sales with a $billion+ sales potential product and FDA approval to enter the POC market is possible in May.